MIND–ME
Microvesicles at the INtersection between Dysbiosis and Major dEpression disorder:
an OMIC approach
Funded by the Cariplo Foundation
MIND–ME
Start date: 01.06.2020
End date: 31.05.2023
36 months
TYPE OF PROJECT
The aim of MIND-ME is to investigate the molecular basis of MDD and find innovative biomarkers to predict clinical outcomes and tailor individualized pharmacological treatments.
Next-generation biobank
Create a next-generation biobank by collecting MDD samples with associated medical and high-throughput biological data, enabling new discoveries and biomarker identification
Cytofluorimetric panel
Develop a cytofluorimetric panel to sort and characterize MVs in MDD, merging transcriptomics/proteomics, with the dynamics of cell and tissue function
Create a relevant antibody panel
Identify key bacteria-derived MVs associated with MDD and create a relevant antibody panel for their analysis
RESEARCH AREA
Major Depressive Disorder (MDD) represents the third in global disability (2.5% of Disability-Adjusted Life Years), mainly affecting women. Moreover, MDD has a high suicide rate (15% of deaths). Guidelines recommend antidepressants as the initial treatment, but 40% don’t achieve remission after four attempts. Diagnostics and prognostic biomarkers are fundamental, given the lack of them.
This proposal seeks to uncover MDD’s molecular basis and discover new biomarkers, enhancing care for non-responsive patients and reducing treatment failures.
HOW WE ARE DOING IT
Research
There is an urgent need to improve the methods of diagnosing, predicting, and treating psychiatric disorders. In the field of psychiatry, there is a lack of definitive biological indicators, or biomarkers, to aid in accurate diagnosis, prognosis, and the selection of optimal therapeutic strategies for individuals with mental disorders. This is particularly relevant in the case of Major Depressive Disorder (MDD), where despite the established efficacy of antidepressants, a significant percentage of patients do not exhibit a satisfactory therapeutic response to initial antidepressant treatments.
Know-how
MIND-ME conducts a clinical study enrolling 100 MDD outpatients, and employs multi-OMIC assays for transcriptomics, proteomics, gut microbiome, and metabolomics to predict a molecular signature for treatment failure. Moreover utilizes networks to identify causative changes and treatment targets focusing on developing diagnostic tests and a personalized therapeutic algorithm for MDD, aiming to reduce treatment failure, improve patient quality of life, and minimize healthcare costs.
THE ROLE OF UPO
CAAD is fully equipped with “omic-platforms” for genomics, trascriptomics, epigenomics, metagenomics, proteomics and metabolomics: a next generation sequencing system, a digital PCR system, two high resolution mass spectrometers for proteomics and metabolomics, a liquid chromatography system for sample fractionation, a liquid handling platform for sample preparation, an automated ELISA platform, a cytometer for the detection of 29 colours simultaneously and for single cells sorting in a 96 well plate an SPR module for molecular interactions, a platform for nanoparticle characterization, a microvolume spectrophotometer, a microplate reader.
Inside the CAAD, an automated biobanking system is specifically dedicated for the collection, storage and remote-record of biological samples, as well as for the data management, whereas a bioinformatic platform/service is specifically committed to big data analysis.
OUR PARTNERS
- Università degli Studi del Piemonte Orientale Amedeo Avogadro (UPO) – Novara, ITALY
- A.O.U. Città della Salute e della Scienza di Torino – Turin, ITALY
USEFUL LINKS
Projects
Team
Cookie policy
Privacy Policy
CONTACTS
CAAD | Corso Trieste 15/A
Novara – 28100, Italy
MIND–ME
Microvesicles at the INtersection between Dysbiosis and Major dEpression disorder:
an OMIC approach
Funded by the Cariplo Foundation
MIND–ME
Start date: 01.06.2020
End date: 31.05.2023
36 months
TYPE OF PROJECT
The aim of MIND-ME is to investigate the molecular basis of MDD and find innovative biomarkers to predict clinical outcomes and tailor individualized pharmacological treatments.
Next-generation biobank
Create a next-generation biobank by collecting MDD samples with associated medical and high-throughput biological data, enabling new discoveries and biomarker identification
Cytofluorimetric panel
Develop a cytofluorimetric panel to sort and characterize MVs in MDD, merging transcriptomics/proteomics, with the dynamics of cell and tissue function
Create a relevant antibody panel
Identify key bacteria-derived MVs associated with MDD and create a relevant antibody panel for their analysis
RESEARCH AREA
Major Depressive Disorder (MDD) represents the third in global disability (2.5% of Disability-Adjusted Life Years), mainly affecting women. Moreover, MDD has a high suicide rate (15% of deaths). Guidelines recommend antidepressants as the initial treatment, but 40% don’t achieve remission after four attempts. Diagnostics and prognostic biomarkers are fundamental, given the lack of them.
This proposal seeks to uncover MDD’s molecular basis and discover new biomarkers, enhancing care for non-responsive patients and reducing treatment failures.
HOW WE ARE DOING IT
Research
There is an urgent need to improve the methods of diagnosing, predicting, and treating psychiatric disorders. In the field of psychiatry, there is a lack of definitive biological indicators, or biomarkers, to aid in accurate diagnosis, prognosis, and the selection of optimal therapeutic strategies for individuals with mental disorders. This is particularly relevant in the case of Major Depressive Disorder (MDD), where despite the established efficacy of antidepressants, a significant percentage of patients do not exhibit a satisfactory therapeutic response to initial antidepressant treatments.
Know-how
MIND-ME conducts a clinical study enrolling 100 MDD outpatients, and employs multi-OMIC assays for transcriptomics, proteomics, gut microbiome, and metabolomics to predict a molecular signature for treatment failure. Moreover utilizes networks to identify causative changes and treatment targets focusing on developing diagnostic tests and a personalized therapeutic algorithm for MDD, aiming to reduce treatment failure, improve patient quality of life, and minimize healthcare costs.
THE ROLE OF UPO
CAAD is fully equipped with “omic-platforms” for genomics, trascriptomics, epigenomics, metagenomics, proteomics and metabolomics: a next generation sequencing system, a digital PCR system, two high resolution mass spectrometers for proteomics and metabolomics, a liquid chromatography system for sample fractionation, a liquid handling platform for sample preparation, an automated ELISA platform, a cytometer for the detection of 29 colours simultaneously and for single cells sorting in a 96 well plate an SPR module for molecular interactions, a platform for nanoparticle characterization, a microvolume spectrophotometer, a microplate reader.
Inside the CAAD, an automated biobanking system is specifically dedicated for the collection, storage and remote-record of biological samples, as well as for the data management, whereas a bioinformatic platform/service is specifically committed to big data analysis.
OUR PARTNERS
- Università degli Studi del Piemonte Orientale Amedeo Avogadro (UPO) – Novara, ITALY
- A.O.U. Città della Salute e della Scienza di Torino – Turin, ITALY
USEFUL LINKS
Projects
Team
Cookie policy
Privacy Policy
CONTACTS
CAAD | Corso Trieste 15/A
Novara – 28100, Italy